Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 282Carcinoma, Non-Small-Cell Lung 253Leukemia, Myeloid, Acute 190Breast Neoplasms 153Melanoma 151Neoplasm Metastasis 148Multiple Myeloma 127Recurrence 123Colorectal Neoplasms 119Lymphoma, Non-Hodgkin 114Lymphoma 113Leukemia, Lymphocytic, Chronic, B-Cell 108Pancreatic Neoplasms 99Ovarian Neoplasms 99Precursor Cell Lymphoblastic Leukemia-Lymphoma 91Leukemia 86Prostatic Neoplasms 83Lung Neoplasms 82Lymphoma, Large B-Cell, Diffuse 77Squamous Cell Carcinoma of Head and Neck 76Glioblastoma 73Carcinoma, Renal Cell 72Myelodysplastic Syndromes 68Lymphoma, Follicular 65Brain Neoplasms 60Lymphoma, Mantle-Cell 55Sarcoma 53Stomach Neoplasms 52Head and Neck Neoplasms 52Triple Negative Breast Neoplasms 51

Interventions

aprutumab ixadotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Terminated × Medical Oncology × Clear all
NCT02368951 2017-07-12

Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)

Bayer

Phase 1 Terminated
20 enrolled

Medical Oncology

Data powered by HemOnc (CC BY 4.0) Colophon âš¡